US Edition'King Kong' weight loss jab Mounjaro hit by NHS postcode lottery
ENGLAND, AUG 5 – Only 8 of 42 NHS Integrated Care Boards offer Mounjaro, with funding for 22,000 of 97,500 eligible patients, causing delays and limited treatment access, NHS data shows.
- The NHS rollout of the weight loss drug Mounjaro for severely obese patients began on June 23 but faces delays and uneven access across England.
- This rollout follows NICE guidance to treat patients with a BMI over 40 plus clinical conditions, yet funding covers just over 22,000 patients of an estimated 97,500 eligible in the first year.
- A recently released quality standard encourages healthcare professionals to provide personalized long-term support, including access to dietitians and community programs, to help prevent patients from regaining weight after medication.
- Dr Yael Wolff Sagy stated injections reduce obesity-related cancer risk by 41% but cautions that the full metabolic benefits of GLP-1 drugs are not yet understood.
- The slow rollout and funding gaps suggest many eligible patients face prolonged waits, highlighting the need for improved NHS access and continuous care for effective weight management.
Insights by Ground AI
Does this summary seem wrong?
10 Articles
10 Articles
Postcode lottery for Mounjaro, the 'King Kong' of weight loss jabs, with only eight NHS care boards providing treatment
Freedom of Information requests by Sky News reveal only eight of 42 NHS Integrated Care Boards in England were providing the weight loss treatment to patients, and many of the rest were unable to guarantee when it would be available.
·United Kingdom
Read Full ArticleCoverage Details
Total News Sources10
Leaning Left3Leaning Right1Center2Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 33%
R 17%
Factuality
To view factuality data please Upgrade to Premium
